top of page


FDA approves Teva's Weltruza as first once-monthly subcutaneous olanzapine injection for schizophrenia
Teva has secured FDA approval for Weltruza, the first once-monthly subcutaneous extended-release olanzapine injection for adults with schizophrenia.

nuaxia
Oct 122 min read


Flow Neuroscience launches first FDA-approved at-home tDCS treatment for depression in the US
Flow Neuroscience has launched FL-100 in the United States, bringing an FDA-approved at-home transcranial direct-current stimulation treatment to adults with moderate-to-severe major depressive disorder.

nuaxia
Sep 172 min read


FDA finalises clinical investigation guidance for psychedelic drug development
The guidance gives sponsors clearer recommendations for addressing trial design, safety monitoring, abuse potential and the operational challenges associated with hallucinogenic drug effects.

nuaxia
Jul 303 min read
bottom of page